Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

• DOI: 10.1111/imj.13311
• Publication Date: 2017-01-13T05:52:47Z
• Authors: Dipti Talaulikar; Constantine S. Tam; Douglas Joshua; Joy Phoebe Ho; Jeff Szer; Hang Quach; Andrew Spencer; Simon Harrison; Peter Mollee; Andrew W. Roberts; Noemi Horvath; Cindy Lee; Andrew Zannettino; Ross Brown; Bradley Augustson; Wilfrid Jaksic; John Gibson; Anna Kalff; Anna Johnston; Judith Trotman; Akash Kalro; George Grigoriadis; Chris Ward; H. Miles Prince
• Keywords: Bendamustine; Lymphoplasmacytic Lymphoma

Waldenström macroglobulinaemia ( WM ) is an indolent B‐cell malignancy characterised by the presence of immunoglobulin M IgM paraprotein and bone marrow infiltration clonal small B lymphocytes, plasmacytoid lymphocytes plasma cells. The symptoms are protean, often follow asymptomatic phase may include complications related to paraneoplastic effects paraprotein. revised 2016 World Health Organization classification includes MYD88 L265P mutation, which seen in >90% cases, within diagnostic criteria for . While treatment has been considered together with other cell lymphomas, there unique aspects management that require specific care. These unreliability measurements monitoring patients prior after treatment, lack correlation between disease burden rituximab‐induced flare. Moreover, while bendamustine rituximab recently approved reimbursed frontline use Australia, regimens, including ibrutinib‐ bortezomib‐based treatments, not funded, requiring tailoring regional regulatory environment. Medical Scientific Advisory Group Myeloma Foundation Australia therefore developed clinical practice guidelines recommendations work‐up therapy assist Australian clinicians this disease.